RE:RE:RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation LS29 ...
Why do you still doubt about the financing when the recent MD&A tells you about the cash on hand we have?
Do you also think Roger and Kristina would have invested their own money in warrants, weeks/months before a pp, especially knowing how close we are before a Breakthrough designation window of opportunity that could reward us with an upfront payment???
You can post about your impatience as long as you want, it all comes down to 2022 clinical data. And unless we can statistically confirm what a durable response can look like, it's way better for us to collect a little bit more data before starting to negotiate something (ink a deal) as we could be much more in the driver's seat than if we do it on vague data. At this point in time, with still money left in the bank, I think TLT management is doing the right thing and Roger is a fierce negotiator. He knows what he has in terms of efficacy when compared with competition and I don't think he will settle for something less than a real valuation.
If we have a treatment that delivers consistency, one optimized patient after another, and that these results are higher than competition, and that these results point toward the next SOC, then one of the big pharmas that has an already established network of distribution in the urology field will have no other choice than to drop immunotherapies and finally recognize the superiority (efficacy) of PDT/PDC over immunotherapies as this all comes down to market shares at the end of the day for these CEOs, no matter the industry. Just like it was, when immunotherapy came in, they are all looking for this next disruptive solution that can allow them to stay ahead of their competitors. It's a question of which one moves faster than its competitors.